Overview

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:
0

Participant gender:
All

Summary

evaluation of the efficacy of transarterial chemoinfusion (TAI) combine lenvatinib in advanced hepatocelllar carcinoma

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Lenvatinib

Criteria

Inclusion Criteria:

older than 18 years old and younger than 75 years; ECOG PS≤1; proven hepatocellular
carcinoma according patological examination or EASL/AASLD diagnostic criteria; not previous
treated for tumor; unresectable; the lab test could meet: neutrophil count≥2.0×109/L;
hemoglobin≥100g/L; platelet count≥75×109/L; serum albumin≥35g/L; total bilirubin<2-times
upper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit of
normal; serum creatine<1.5-times upper limit of normal; PT≤upper limit of normal plus 4
seconds; INR≤2.2; sign up consent

Exclusion Criteria:

cannot tolerate TAI or surgery; known history of other malignancy; be allergic to related
drugs; underwent organ transplantation before; be treated before (interferon included);
known history of HIV infection; known history of drug or alcohol abuse; have GI hemorrhage
or cardiac/brain vascular events within 30 days; pregnancy